The MiningNewsWire Podcast

The search for ways to improve mental health is driving expansion for a variety of companies looking to offer effective solutions, including treatments that are tapping into the power of psychedelic mushrooms.

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) is one of the innovators in this field, expanding through acquisitions and outside funding to support R&D and a growing product line focused on artisanal medical mushroom formulations and mushroom-infused functional beverage CPGs. It’s a range of products set to appeal to markets similar to Herbalife Nutrition Ltd. (NYSE: HLF), which provides nature-based products for physical and mental health. Biopharmaceutical company Axsome Therapeutics Inc. (NASDAQ: AXSM) is also tackling serious depression, with a new drug currently undergoing trials. Allergan (NYSE: AGN) has recently announced a new drug to tackle bipolar disorder, with a single treatment for both manic and depressive phases. Meanwhile Johnson & Johnson (NYSE: JNJ) is showing the power of previously scorned drugs with a ketamine-based depression treatment.